⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28929502 | 1.00 | — | — | |
| SCHEMBL25238195 | 0.83 | BRD4 (0.35) | — | |
| SCHEMBL25280759 | 0.81 | CRBN (0.40) | — | |
| SCHEMBL16119357 | 0.80 | SLC6A1 (0.32) | — | |
| SCHEMBL2391937 | 0.78 | — | — | |
| SCHEMBL24456693 | 0.78 | — | — | |
| SCHEMBL19611118 | 0.78 | — | — | |
| SCHEMBL7030866 | 0.78 | — | — | |
| SCHEMBL24630408 | 0.77 | — | — | |
| SCHEMBL524142 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118647378-A | Inhibitors of Mei Nen protein interaction with MLL | 巴拉疗法公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118215652-A | Substituted hydroxymethyl pyrrolidines and medical uses thereof | 阿托基公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| EP-2091538-A2 | 4-BENZYL-L(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008149191-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-5552545-A | 5-deaza-10-oxo-and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5321150-A | 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids | ELI LILLY AND COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0552552-A2 | 5-Deazafolic acid derivatives and their use as antineoplastics agents | ELI LILLY AND COMPANY (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5159079-A | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |